Nefiracetam$29.99 USD
← Catalog
NefiracetamFor research use only. Not for human consumption.
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
CAS 77191-36-7 · 50 × 20 mg · 1000 mg total
98.0%
qNMR spec ≥98%
View COA →
50 × 20mg Nefiracetam. Research use only.
$29.99 USD
$0.60 per unit
Researchers also ordered
TAK-653
49% of buyers of this compound
$39.99 USD
TAK-653
49% of buyers of this compound
$39.99 USD
Research use only · Not for human or animal consumption
Batch and analysis
- Batch
- PCS-NEFI-2608A
- Assay method
- qNMR · third party
- Release spec
- ≥ 98%
- CAS
- 77191-36-7
- Systematic name
- N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
- Presentation
- 50 × 20 mg · 1000 mg total
- Purity result
- 98.0% (qNMR · third party), lot PCS-NEFI-2608A
- Also known as
- DM-9384
- Molecular formula
- C14H18N2O2
- Molecular weight
- 246.30 g/mol
- PubChem CID
- 71157
About this compound
For In Vitro Research Use Only – Not for Human or Veterinary Application
Nefiracetam (DM-9384)
Daiichi Seiyaku in Tokyo developed nefiracetam in the late 1980s. It is a racetam: N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide, C14H18N2O2, 246.30 g/mol, CAS 77191-36-7, PubChem CID 71157. Daiichi took it through Phase 3 studies in Japan and withdrew its Japanese application in February 2002. It isn't approved anywhere.
One compound, several targets
Unlike most racetams, nefiracetam has detailed electrophysiology behind it, and that work points at more than one system:
| Target | Reported effect | System |
|---|---|---|
| L-type Ca²⁺ channels | Increased currents through Gi/Go G proteins, bell-shaped concentration curve | NG108-15 cells |
| Nicotinic α4β2 receptors | Potentiation at nanomolar concentrations, through PKA and PKC | Rat cortical neurons, oocytes |
| NMDA receptors | Potentiation through PKCα and reduced Mg²⁺ block | Neurons (electrophysiology) |
| Transmitter turnover | Increased cholinergic and GABAergic turnover | Rat brain |
Which of these is primary hasn't been resolved. Its hippocampal effects also look pharmacologically distinct from piracetam's and aniracetam's.
Breadth of research
A large rodent literature covers amnesia models (scopolamine, electroconvulsive shock, cycloheximide, basal-forebrain lesion), ischemia, traumatic brain injury, seizure and neuropathic-pain models. There is also eyeblink conditioning in older rabbits and a 1994 toxicology series in rats, dogs and rabbits. In that series, renal papillary necrosis appeared only in dogs, linked to a metabolite (M-18). More recently it came up as one of two leads that reversed synaptic phenotypes in human stem-cell MECP2-knockout neurons and organoids.
Our lot
Lot PCS-NEFI-2608A: 98.0% by quantitative NMR, NuMega Resonance Labs, report dated August 10, 2026. 50 capsules of 20 mg per bottle, 1,000 mg in total.
References
- Ca²⁺ channel and G-protein work: PMID 8032872
- Nicotinic α4β2 potentiation: PMID 11259610
- NMDA and PKCα: PMID 17095583
- Development history to 2002: PMID 12090554
- MECP2 neurons and organoids (2021): PMID 33501759
- PubChem: CID 71157
Disclaimer
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must follow institutional and regulatory guidelines.
Terms of Sale
By purchasing, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance. Nefiracetam reference material is supplied for qualified in vitro laboratory research only — not for human or veterinary consumption, administration, compounding, dispensing, diagnostic use, therapeutic use, or patient use.